MCID: OVR010
MIFTS: 39

Ovarian Brenner Tumor

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Brenner Tumor

MalaCards integrated aliases for Ovarian Brenner Tumor:

Name: Ovarian Brenner Tumor 12 20 15
Benign Ovarian Brenner Tumor 12 17
Brenner Tumor 44 70
Benign Ovarian Brenner Tumour 12
Ovarian Brenner Tumour 12
Brenner Tumor of Ovary 20
Benign Brenner Tumor 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2636
MeSH 44 D001948
NCIt 50 C39954
UMLS 70 C0006160 C0474834

Summaries for Ovarian Brenner Tumor

GARD : 20 Brenner tumor of the ovary is a solid, abnormal growth (tumor) on the ovary. Most Brenner tumors are not cancerous (benign). About 5% of Brenner tumors are cancerous (malignant) or have a small chance of spreading beyond its original location (borderline). These tumors most often occur in women after menopause. They usually do not cause symptoms unless they are very large. When symptoms are present, they may include abdominal pain or vaginal bleeding. The cause of Brenner tumors is unknown. They are usually found by accident during surgery for another reason or during a routine doctor's examination. The diagnosis is made by microscopic examination of a piece of tumor obtained by a surgical biopsy. Treatment usually consists of surgery to remove the tumor. If a Brenner tumor has not spread into surrounding tissues or to more distant parts of the body, there is a good-to-excellent long-term outcome.

MalaCards based summary : Ovarian Brenner Tumor, also known as benign ovarian brenner tumor, is related to teratoma and cystic teratoma. An important gene associated with Ovarian Brenner Tumor is UPK3A (Uroplakin 3A), and among its related pathways/superpathways are HIF1Alpha Pathway and Oncogene Induced Senescence. The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and uterus, and related phenotype is renal/urinary system.

Disease Ontology : 12 An ovarian benign neoplasm that has material basis in the surface epithelium of the ovary.

Related Diseases for Ovarian Brenner Tumor

Diseases in the Ovarian Brenner Tumor family:

Malignant Ovarian Brenner Tumor

Diseases related to Ovarian Brenner Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 teratoma 30.3 KRT7 KRT20 CDKN2A
2 cystic teratoma 30.2 KRT7 KRT20 CDKN2A
3 cystadenoma 30.1 KRT7 KRT20
4 pleomorphic liposarcoma 30.1 MDM2 CDKN2A
5 ovarian mucinous neoplasm 30.1 KRT7 KRT20
6 spindle cell sarcoma 30.1 MDM2 KRT7
7 cystadenofibroma 30.0 WT1 KRT7
8 clear cell adenocarcinoma 29.9 KRT7 KRT20
9 appendix adenocarcinoma 29.9 KRT7 KRT20
10 papillary cystadenocarcinoma 29.9 KRT7 KRT20
11 papilloma 29.8 KRT7 KRT20 CDKN2A
12 leiomyosarcoma 29.8 WT1 MDM2 CDKN2A
13 adenocarcinoma 29.8 MDM2 KRT7 KRT20 CDKN2A
14 bladder urothelial carcinoma 29.6 UPK3A KRT20 CDKN2A
15 adenoma 29.6 KRT7 KRT20 CDKN2A
16 cervical adenocarcinoma 29.6 KRT7 KRT20 CDKN2A
17 mucinous adenocarcinoma 29.6 KRT7 KRT20 CDKN2A
18 intestinal obstruction 29.6 KRT7 KRT20
19 transitional cell carcinoma 29.4 UPK3A MDM2 KRT7 KRT20 CDKN2A
20 rhabdomyosarcoma 29.3 WT1 MDM2 KRT7 CDKN2A
21 endometrial cancer 29.3 WT1 MDM2 KRT7 KRT20 CDKN2A
22 benign mesothelioma 28.8 WT1 THBD KRT7 KRT20 CDKN2A
23 malignant ovarian brenner tumor 11.5
24 brenner tumor of the vagina 11.3
25 testicular brenner tumor 11.3
26 struma ovarii 10.4
27 mediastinum liposarcoma 10.2 MDM2 CDKN2A
28 esophagus verrucous carcinoma 10.2 MDM2 CDKN2A
29 verrucous carcinoma 10.2 MDM2 CDKN2A
30 inflammatory liposarcoma 10.2 MDM2 CDKN2A
31 pancreas sarcoma 10.2 MDM2 CDKN2A
32 infiltrating angiolipoma 10.2 MDM2 CDKN2A
33 hereditary melanoma 10.2 MDM2 CDKN2A
34 cervical basaloid squamous cell carcinoma 10.2 KRT7 CDKN2A
35 fallopian tube squamous cell carcinoma 10.2 WT1 CDKN2A
36 familial retinoblastoma 10.2 MDM2 CDKN2A
37 inverted transitional papilloma 10.2 KRT7 CDKN2A
38 anal canal paget's disease 10.2 KRT7 CDKN2A
39 cervical adenoid cystic carcinoma 10.2 KRT7 CDKN2A
40 anal squamous cell carcinoma 10.2 MDM2 CDKN2A
41 papillary squamous carcinoma 10.2 KRT7 CDKN2A
42 gliomatosis cerebri 10.2 MDM2 CDKN2A
43 gallbladder adenoma 10.2 KRT7 CDKN2A
44 keratinizing squamous cell carcinoma 10.1 KRT7 CDKN2A
45 transitional papilloma 10.1 UPK3A KRT7
46 renal pelvis transitional cell carcinoma 10.1 UPK3A KRT7
47 adenomyoma 10.1 KRT7 CDKN2A
48 estrogen excess 10.1
49 ovarian epithelial cancer 10.1
50 vaginal cancer 10.1 KRT7 CDKN2A

Graphical network of the top 20 diseases related to Ovarian Brenner Tumor:



Diseases related to Ovarian Brenner Tumor

Symptoms & Phenotypes for Ovarian Brenner Tumor

MGI Mouse Phenotypes related to Ovarian Brenner Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.02 KRT7 MDM2 THBD UPK3A WT1

Drugs & Therapeutics for Ovarian Brenner Tumor

Drugs for Ovarian Brenner Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
7
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
8
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
9 Carotenoids Phase 3
10 Immunosuppressive Agents Phase 3
11 Immunologic Factors Phase 3
12 Antiviral Agents Phase 3
13 Antimetabolites Phase 3
14 Anti-Infective Agents Phase 3
15 Tubulin Modulators Phase 3
16 Antibodies Phase 3
17 Antineoplastic Agents, Immunological Phase 3
18 Immunoglobulins, Intravenous Phase 3
19 Immunoglobulins Phase 3
20 Angiogenesis Inhibitors Phase 3
21 Albumin-Bound Paclitaxel Phase 3
22 Antibodies, Monoclonal Phase 3
23 Antimitotic Agents Phase 3
24 Mitogens Phase 3
25 Immunoglobulin G Phase 3
26 Endothelial Growth Factors Phase 3
27 taxane Phase 3
28
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
29
Belinostat Approved, Investigational Phase 2 866323-14-0
30
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
31
Metformin Approved Phase 2 657-24-9 4091 14219
32
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
33
Molgramostim Investigational Phase 2 99283-10-0
34
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
35 Imatinib Mesylate Phase 2 220127-57-1 123596
36 Protein Kinase Inhibitors Phase 2
37
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
38 Histone Deacetylase Inhibitors Phase 2
39 Pharmaceutical Solutions Phase 2
40 Hypoglycemic Agents Phase 2
41
Topotecan Approved, Investigational Phase 1 123948-87-8, 119413-54-6 60700
42
Lenograstim Approved, Investigational Phase 1 135968-09-1
43
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
44
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
45
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
46
7-hydroxystaurosporine Experimental, Investigational Phase 1 112953-11-4 72271
47
Veliparib Investigational Phase 1 912444-00-9 11960529
48 topoisomerase I inhibitors Phase 1
49 Antibiotics, Antitubercular Phase 1
50
Liposomal doxorubicin Phase 1 31703

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
4 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
5 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
6 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
7 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
8 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
9 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
10 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
11 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
12 A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors Completed NCT00301756 Phase 2 Belinostat
13 A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum Completed NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate
14 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
15 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
16 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
17 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
18 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
19 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
20 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
21 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00079430 Phase 1 paclitaxel;carboplatin
22 A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
23 PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
24 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
25 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
26 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
27 A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
28 A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
29 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
30 A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT01080521
31 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
32 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial Recruiting NCT03641287
33 Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy Terminated NCT01275664 Aprepitant;Carboplatin;Cisplatin;Dexamethasone;Granisetron Transdermal Patch
34 A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Ovarian Brenner Tumor

Cochrane evidence based reviews: brenner tumor

Genetic Tests for Ovarian Brenner Tumor

Anatomical Context for Ovarian Brenner Tumor

MalaCards organs/tissues related to Ovarian Brenner Tumor:

40
Ovary, Endothelial, Uterus, Cervix, Testis, Thyroid, Skin

Publications for Ovarian Brenner Tumor

Articles related to Ovarian Brenner Tumor:

(show top 50) (show all 431)
# Title Authors PMID Year
1
Malignant Brenner tumors of the ovary; a population-based analysis. 61 20
27130406 2016
2
A rare malignant Brenner tumor of the ovary in a 77-year-old woman: a case report. 61 54
19769199 2009
3
Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. 61 54
14576476 2003
4
Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. 54 61
11253121 2001
5
Malignant Brenner tumors of the ovary and tumor markers: case reports. 61 54
10418561 1999
6
Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. 61 54
8811388 1996
7
Borderline Brenner Tumor of the Ovary Coexisting With an Ovarian Mucinous Cystadenoma With Focal Atypical Epithelial Proliferation: A Rare Case With Review of the Literature. 61
33635096 2021
8
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. 61
33077920 2020
9
Benign Brenner Tumor in an Ectopic Ovary: A Case Report and Review of Literature. 61
32947329 2020
10
A case of a vaginal Brenner tumor without a gland mimicking a borderline tumor: unusual morphology and diagnostic pitfalls. 61
32809866 2020
11
Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor? 61
32322877 2020
12
Two types of primary mucinous ovarian tumors can be distinguished based on their origin. 61
31695154 2020
13
Extraovarian Brenner tumor in the uterus: a case report and review of literature. 61
32164751 2020
14
MRI and FDG PET/CT Findings for Borderline Brenner Tumor of the Ovary: A Case Report and Literature Review. 61
32879741 2020
15
Radiographic Features of a Benign Mixed Brenner Tumor and Mucinous Cystadenoma: A Rarely Identified Ovarian Neoplasm on Imaging. 61
32363084 2020
16
Coexistence of Benign Brenner Tumor with Mucinous Cystadenoma in an Ovarian Mass. 61
32944047 2020
17
Ovarian Mixed Malignant Brenner-Mucinous Tumor with Signet Ring Cells. 61
32274235 2020
18
A Rare Case of Grade 1 Endometrioid Adenocarcinoma of the Uterus With Omental Metastasis with Brenner Tumor of the Ovary in a Postmenopausal Female. 61
32684728 2020
19
[Malignant Brenner tumor with a functioning stroma in elderly woman: report of a case]. 61
31818078 2019
20
Ovarian Combined Brenner Tumor, Mucinous Cystadenoma and Struma Ovarii: First Report of a Rare Combination. 61
30134344 2019
21
Primary Squamous Cell Carcinoma of the Ovary. 61
31772854 2019
22
Borderline Brenner Tumor: A Review of the Literature. 61
30779594 2019
23
Synchronous benign Brenner's tumor of ovary with leiomyoma and endometrial adenocarcinoma in a postmenopausal female. 61
31898686 2019
24
Primary squamous cell carcinoma of the ovary. Review of the literature. 61
31786837 2019
25
Malignant Brenner tumor of the ovary: Case series and review of treatment strategies. 61
30815527 2019
26
Ovarian mucinous cystic tumor associated with sarcomatous mural nodule and benign Brenner tumor: A case report and literature review. 61
30653119 2019
27
Incidental Gynecologic Tract Neoplasms in Women Undergoing Anterior Pelvic Exenteration for Urothelial Carcinoma. 61
29257039 2019
28
[Demons-Meigs syndrome secondary to an ovarian Brenner tumour. Case report and literature survey]. 61
30570232 2018
29
Malignant Brenner tumor: Two case reports. 61
30364765 2018
30
Computed tomography imaging features of benign ovarian Brenner tumors. 61
30061939 2018
31
Mixed Ovarian Tumor Composed of Brenner Tumor and Adult-Type Granulosa Cell Tumor: A Case Report of a Very Rare Mixed Ovarian Tumor and a Review of the Literature. 61
29198156 2018
32
Ovarian borderline mucinous tumor with squamous overgrowth: An unusual finding with review of literature. 61
29676373 2018
33
Squamous Cell Carcinoma Arising in Mature Teratoma of the Ovary Masquerading as Abdominal Tuberculosis. 61
29628730 2018
34
Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network. 61
28821472 2018
35
Brenner tumor of the ovary - ultrasound features and clinical management of a rare ovarian tumor mimicking ovarian cancer. 61
30091444 2018
36
A case report of an incidental Brenner tumor found after resection of a large ovarian mucinous neoplasm. 61
29960208 2018
37
Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor. 61
29567918 2018
38
Malignant Brenner tumor of the ovary: Review and case report. 61
28971141 2017
39
Ovarian torsion of mixed epithelial tumor misdiagnosed as a malignancy in postmenopausal woman: A case report. 61
28984773 2017
40
Malignant Brenner tumor associated with a germline BRCA2 mutation. 61
28616458 2017
41
Malignancy risk of sonographically benign appearing purely solid adnexal masses in asymptomatic postmenopausal women. 61
28118296 2017
42
Features of ovarian Brenner tumors: Experience of a single tertiary center. 61
28913150 2017
43
Vaginal Brenner tumor with literature review: does this tumour originate from Walthard nests? 61
28413211 2017
44
Coexisting Brenner Tumor and Endometrial Carcinoma. 61
28706410 2017
45
A peculiar case report of extraovarian Brenner tumor arising in the omentum. 61
28351362 2017
46
Brenner tumor of the testis: A case report and review of the literature. 61
28123743 2017
47
Laparoscopic treatment of Castleman's disease in a patient with a history of malignant Brenner tumor. 61
27751433 2016
48
Testosterone Aromatization to Estradiol in Course of Ovarian Functioning Brenner Tumor Associated With Endometrial Carcinoma and Endometriosis (Roncati-Manenti Triad). 61
27465894 2016
49
Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma. 61
27299795 2016
50
Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification. 61
26797085 2016

Variations for Ovarian Brenner Tumor

Expression for Ovarian Brenner Tumor

Search GEO for disease gene expression data for Ovarian Brenner Tumor.

Pathways for Ovarian Brenner Tumor

Pathways related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.05 MDM2 CDKN2A
2 10.76 MDM2 CDKN2A
3 10.66 UPK3A MDM2 CDKN2A
4
Show member pathways
10.5 MDM2 CDKN2A
5 10.3 MDM2 CDKN2A

GO Terms for Ovarian Brenner Tumor

Biological processes related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein destabilization GO:0031648 8.96 MDM2 CDKN2A
2 amyloid fibril formation GO:1990000 8.62 MDM2 CDKN2A

Molecular functions related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.96 MDM2 CDKN2A
2 SUMO transferase activity GO:0019789 8.62 MDM2 CDKN2A

Sources for Ovarian Brenner Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....